Minerva Advisors’s Oruka Therapeutics ORKA Stock Holding History

Minerva Advisors’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-833	Closed	-$30K	–	73
2021 Q3	$30K	Buy	+833	New	+$30.8K	0.02%	73

Other funds holding ORKA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Minerva Advisors's ORKA Position: Q4 2021 in Review

Minerva Advisors sold out of Oruka Therapeutics (ORKA) in Q4 2021, closing a stake of 833 shares — an estimated $30K sold.

Minerva Advisors first reported a position in ORKA in Q3 2021 and held it in 1 quarter. The position peaked at $30K in Q3 2021. 20 funds tracked by Wall St. Rank hold ORKA as of Q4 2021.

Minerva Advisors reported no remaining Oruka Therapeutics position as of Q4 2021 after selling out during the quarter.
Minerva Advisors sold 833 Oruka Therapeutics shares in Q4 2021, an estimated $30K.
Minerva Advisors first reported a position in Oruka Therapeutics in Q3 2021 and held it in 1 quarter.
Minerva Advisors's Oruka Therapeutics position peaked at $30K in Q3 2021.
20 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q4 2021.

Based on Minerva Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.